<DOC>
	<DOC>NCT00147537</DOC>
	<brief_summary>Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer</brief_summary>
	<brief_title>Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosis of advanced/metastatic lung cancer Previous treatment with chemotherapy Uncontrolled diabetes History/active cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>figitumumab</keyword>
	<keyword>insulin-like growth 1 factor receptor</keyword>
	<keyword>IGF-IR</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>